N-acetylglutamate synthase deficiency

Neurogenetic Disorders

Updated 02.27.2024
Released 03.27.1995
Expires For CME 02.27.2027

N-acetylglutamate synthase deficiency

Authors: Roland Posset MD, Matthias Zielonka MD, Georg F Hoffmann MD

See Contributor Disclosures

Editor: Barry Wolf MD PhD

N-acetylglutamate synthase deficiency

In This Article

Quick Link

Introduction

Overview

N-acetylglutamate synthase deficiency is an inherited urea cycle disorder that causes hyperammonemia and neurologic sequelae, and most importantly, intellectual disability and early death. N-acetylglutamate synthase (NAGS) plays a determinant role in regulating the urea cycle at the entry point and connects energy metabolism with nitrogen disposal. Primary genetic enzyme deficiency almost invariably results in hyperammonemic coma within the first weeks of life (≤ 28 days; neonatal/early onset), whereas presentation at a later stage of life (> 28 days; late onset) has very rarely been reported so far. Biochemical markers include elevated plasma glutamine and normal to reduced L-arginine and/or L-citrulline concentrations on amino acid analysis. Diagnosis is established by molecular genetic analysis or, rarely, by enzymatic testing. Treatment consists of long-term oral therapy with N-carbamylglutamate. It should be noted, however, that a successful therapeutic trial with N-carbamylglutamate is not diagnostic of primary N-acetylglutamate synthase deficiency because the drug may also lower elevated ammonia concentrations in some patients with organic acidurias or carbamylphosphate synthetase 1 deficiency, especially when added to the emergency treatment. N-carbamylglutamate is potentially of use in the treatment of other secondary conditions that interfere with N-acetylglutamate synthase activity. Secondary functional deficiencies occur whenever the synthesis of either of the substrates, acetyl-CoA or glutamate, is insufficient or when other substrates (eg, pathological acyl-CoAs) interfere or compete with acetyl-CoA for NAGS activity. This is the case if intermediates of amino and/or fatty acid metabolism or certain drugs (eg, valproate or pivalate-ester antibiotics) accumulate.

International networks for rare metabolic diseases (UCDC, E-IMD, JUCDC) aim to more completely describe the natural history, especially the initial and long-term evolving clinical phenotype of patients with urea cycle disorders, such as N-acetylglutamate synthase deficiency. Furthermore, they want to determine if the natural disease course can be favorably modulated by diagnostic and therapeutic interventions. These networks collect systematic data to improve the clinical knowledge, develop guidelines, and provide patients and professionals with reliable data on disease manifestation, complications, as well as long-term outcomes of urea cycle disorders. These networks include the Urea Cycle Disorders Consortium (UCDC), established in 2006, the European Registry and Network for Intoxication Type Metabolic Diseases (E-IMD), established in 2011, and the Japanese Urea Cycle Disorders Consortium (JUCDC), established in 2012 (61).

Key points

	• N-acetylglutamate synthase deficiency is a rare urea cycle disorder that causes hyperammonemia, neurologic sequelae, and intellectual disability.
	• Disease manifestations occur most often within the first days of life (early onset 28 or fewer days) and less commonly after the neonatal period (late onset more than 28 days).
	• Neurologic outcome depends on noninterventional parameters, eg, intrinsic disease severity (reflected by onset type and initial peak plasma ammonium concentration during first metabolic decompensation). The impact of interventional parameters, eg, diagnostic and therapeutic interventions, on clinical outcomes remains to be elucidated.
	• Therapy is based on principles of acute and long-term management including administration of N-carbamylglutamate.

Historical note and terminology

N-acetylglutamate synthase deficiency (NAGSD) was first described in 1981 in a male baby and had presumably occurred in two of his siblings who had died in the neonatal period (06). N-acetylglutamate synthase deficiency was considered and the patient successfully treated with benzoate, and later with carbamylglutamate and arginine. N-acetylglutamate synthase deficiency is caused by a deficiency of N-acetylglutamate synthase, which catalyzes the synthesis of N-acetylglutamate from acetyl-CoA and glutamate.

Ammonia is detoxified through its conversion to urea by the enzymes in the small boxes

Ammonia is detoxified through its conversion to urea by the enzymes in the small boxes, whose abbreviations are spelled out below. NAGS catalyzes the synthesis of N-acetylglutamate from acetyl-CoA and glutamate. Deficiency of NAGS...

N-acetylglutamate is the required allosteric activator of carbamoylphosphate synthetase 1 (CPS1), the first and rate-limiting enzyme of the urea cycle (01).

Clinical manifestations

Presentation and course

The classic presentation of N-acetylglutamate synthase deficiency is a catastrophic illness in the first week(s) of life, (neonatal-/early-onset).

Ammonia is detoxified through its conversion to urea by the enzymes in the small boxes

Typically, the affected neonate is born after an uncomplicated, full-term pregnancy, labor, and delivery with normal Apgar scores. Symptoms have mirrored other urea cycle disorders and remind of a neonatal sepsis-like picture with hyperventilation, respiratory distress, and temperature instability. Poor sucking, vomiting, muscular hypotonia, and abnormal motor functions may be observed (39; 40; 34). Hepatomegaly and abnormal liver function tests are mostly evident during these episodes, and liver biopsy shows microvesicular and macrovesicular fat and mitochondria of irregular size and shape with intracristae crystallizations (67). Typically, symptoms rapidly progress from somnolence and lethargy to hyperammonemic coma (25). Convulsions may already be late complications following alterations in consciousness.

Cases of late-onset disease with partial deficiencies have been less commonly reported (13). Symptoms may develop from infancy to adulthood and are associated with weaning or switching from formula to cow's milk, high-protein intake (eg, barbecue, parenteral nutrition), or triggers of catabolic stress. Such triggers might be fever, infections, gastrointestinal bleeding, vomiting, decreased energy or increased protein intake, seizures, trauma or burns, and surgery. Furthermore, severe exercise, drugs (steroids, valproate, haloperidol, and L-asparaginase/pegaspargase), chemotherapy, and the postpartum period (due to catabolism and the involution of the uterus) are important triggers for late-onset hyperammonemia (49; 41).

Clinically, late-onset N-acetylglutamate synthase deficiency manifests with recurrent episodes of headache, vomiting, nausea, ataxia, irritability, and behavioral changes, and these may progress to severe lethargy or coma (14; 34). Therefore, due to this broad phenotypic spectrum, maintaining a high index of suspicion at any age is needed for early diagnosis (03).

Data from Europe describing the initial phenotypic presentation of urea cycle disorders suggested that the median age of diagnosis for patients suffering from N-acetylglutamate synthase deficiency was 7 days (39). Acute hyperammonemic episodes cause diffuse or focal patterns of cerebral MRI changes and signs of brain edema (15; 24). However, the impact of acute cerebral changes on long-term outcome; thus, the predictive value of acute MRI changes is unclear. An analysis of MRIs during a stable metabolic condition of individuals with ornithine transcarbamylase deficiency, another urea cycle disorder, showed structural, biochemical, and functional changes in the brain between symptomatic subjects as compared to normal controls (22). Published results from the UCDC reported neurocognitive findings in more than 600 urea cycle disorder patients, including patients suffering from NAGSD (68). In some disorders, adults performed less well than younger patients in neurocognition; however, it remains unclear whether this is due to decline throughout life or improvements in diagnostics and treatments. Patients suffering from NAGSD (n = 4) tended not to have declining scores over time; however, considering the low number of patients, follow-up studies will have to prove this observation.

Prognosis and complications

Morbidity in urea cycle disorders remains high in survivors of neonatal hyperammonemic coma. Frequent comorbidities in urea cycle disorders are associated with the most vulnerable organ, ie, the brain, leading to intellectual disability, cerebral palsy, seizure, as well as movement and speech disorders (40). Data demonstrate that neurocognitive outcome does essentially depend on the initial and peak-blood ammonia level (PBAL) (05; 17; 54). During the first hyperammonemic episode, peak-blood ammonia level of less than 180 µmol/L is associated with a good outcome, and peak-blood ammonia level of more than 360 µmol/L is a marker for poor prognosis. Variable outcome is observed when peak-blood ammonia level is between 180 µmol/L and 360 µmol/L (38). A detailed overview of organ-specific disease manifestations and complications in patients suffering from urea cycle disorders (eg, NAGSD) is given by Kölker and colleagues (40). Moreover, individuals with urea cycle disorders suffer from increased frequencies of mental disability and behavioral/emotional problems. Interestingly, health-related quality of life of these patients is within the normal range (33).

Clinical vignette

Patient 1: Late-onset N-acetylglutamate synthase deficiency. The girl was born to nonconsanguineous parents after a normal pregnancy. Delivery, birth weight, length, head circumference, and neonatal period were all normal. Breast and bottle feeding were well-tolerated, and the developmental milestones were normal. At 13 months of age, vomiting, somnolence, and muscular hypotonia were treated by standard intravenous rehydration therapy. The child recovered completely after 24 hours. Despite the absence of evidence, this episode was interpreted as drug intoxication. In childhood, aversion to protein-rich food resulted in a self-chosen lacto-vegetarian diet. Growth was on the 25th percentile despite periods of lack of appetite. At 12 years of age, during an acute illness confusion, aggressiveness and somnolence developed, which led the physician to suspect encephalitis. A normal cerebrospinal fluid cell count, protein level, and absence of infectious agents did not support this diagnosis. Cranial CT was normal. She recovered completely after 12 hours of 5% glucose and electrolyte infusions. At 13 years of age, she was admitted to a hospital after a protein-rich meal. Symptoms included restlessness, disorientation, aggressiveness, ataxia, increased deep tendon reflexes, and dilated pupils with delayed pupillary reflexes. Cerebrospinal fluid analysis was again normal. There were no signs of cerebral edema on neuroimaging. Biochemical workup showed normal glucose, acid-base balance, electrolytes, creatine and creatine kinase, but plasma ammonia was increased to 221 µmol/L (normal less than 50 µmol/L). Orotic acid excretion was not increased. Amino acids in plasma showed glutamine concentration at the upper normal limit with a glutamine to ammonia ratio of 3.8; this rendered a portosystemic bypass unlikely. Citrulline was 12 µmol/L (normal is 15 to 55 µmol/L), and there was no evidence of a respiratory chain defect that can also lead to low citrulline concentration. There was no arginine deficiency. Urinary organic acid analysis was normal. With other metabolic disorders excluded, carbamylphosphate synthetase 1 or N-acetylglutamate synthase deficiencies were considered possible diagnoses. Restriction of natural protein and substitution of L-arginine and sodium benzoate or phenylbutyrate had not completely normalized ammonia or glutamine concentrations; this in part might retrospectively be due to the excessive protein restriction. An open liver biopsy resulted in the diagnosis of a partial N-acetylglutamate synthase deficiency (15% of lower normal limit measured under optimized conditions) with normal carbamylphosphate synthetase 1 and ornithine transcarbamylase activity. A therapeutic trial with N-carbamylglutamate was successful and allowed a normal protein diet and withdrawal of all other medications. She has since done well with no further metabolic crises on daily treatment of N-carbamylglutamate.

Patient 2: Early-onset N-acetylglutamate synthase deficiency. A 7-day-old formula-fed female, the second child of consanguineous parents, born at term without complications with a birth weight of 3070 g was admitted to a peripheral hospital for a 1-day history of lethargy, poor feeding, and vomiting without diarrhea. She was treated with an oral rehydration solution overnight and subsequently developed a brief episode of supraventricular tachycardia. She was then transferred to the intensive care unit where she arrived lethargic, mildly hypotonic, with incomplete Moro and poor sucking reflexes. Her cardio-respiratory and abdominal examinations were uneventful. A metabolic work-up revealed a blood ammonia level of 290 µmol/L (normal < 100 µmol/l in neonates) with a compensated respiratory alkalosis (pH of 7.48, pCO2 of 19 mmHg, bicarbonate of 14 mmol/L and base excess of 6.6 mmol/L). This was accompanied by normal lactate, normal glucose, and the absence of ketones in the urine. Protein intake was stopped, and an infusion of 20 % glucose was started to achieve a high energy intake. Treatment with sodium benzoate and arginine hydrochloride was initiated. After an initial drop of ammonium within 12 hours of treatment, levels started rising again. N-carbamylglutamate was added, which resulted in the normalization of ammonia. Within 24 to 36 hours oral feeding was progressively reintroduced. The closely monitored ammonium levels remained within the normal range. Further metabolic work-up revealed an increased plasma level of glutamine (1004 µmol/L), but normal levels of citrulline, arginine, ornithine, and normal urine argininosuccinic acid. This suggested a proximal block of the urea cycle. Because urinary orotic acid analysis was also normal, ornithine transcarbamylase deficiency could be ruled out. Genetic analysis confirmed N-acetylglutamate synthase deficiency with a homozygous mutation (c.1450C> T; p.W484R). Both parents were heterozygous for the same mutation. L-arginine and sodium benzoate were stopped. At the age of 9 months, the child was on monotherapy with N-carbamylglutamate and on a normal diet. Growth parameters were within normal limits. Her psychomotor development was normal for a 9-month-old infant; she was sitting without support and had started to crawl. She grasped objects with both hands and transferred them from one hand to the other. Overall, her movements were fluent and well-coordinated. She babbled, waved goodbye, and had good social interaction. This case shows that early treatment of N-acetylglutamate synthase deficiency with N-carbamylglutamante can result in a normal neurologic outcome (65).

Biological basis

Etiology and pathogenesis

This disorder is caused by a complete or partial deficiency of N-acetylglutamate synthase (EC 2.3.1.1). The human gene including frameshift mutation by one base-pair insertion in a patient was found by Elpeleg and colleagues (16). The human and mouse protein (12) share 84% identity. More than 30 mutations have been described with approximately two thirds being missense mutations (11; 28; 26; 56). In addition, regulatory regions might be affected as molecular causes of N-acetylglutamate synthase deficiency are detected more frequently (69; 27). Disease-causing mechanisms appear to involve decreased solubility/stability, aberrant kinetics/catalysis, and altered arginine modulation (56). Based on a NAGS knockout mouse, it was demonstrated that NAGS deficiency can be rescued by gene therapy and that L-arginine is essential to the NAGS enzyme for normal ureagenesis (59). There are no prevalent mutations, and there is uncertainty about the impact of functional data on clinical long-term outcome variables due to a lack of systematic (functional) genotype-phenotype analyses.

N-acetylglutamate synthase is a mitochondrial hepatic enzyme that catalyzes the formation of N-acetylglutamate from acetyl-CoA and glutamate.

Ammonia is detoxified through its conversion to urea by the enzymes in the small boxes

It is also expressed to a minor degree in the intestine. N-acetylglutamate formation depends on substrate availability and is stimulated by mitochondrial arginine. N-acetylglutamate breakdown is decreased by ornithine supplements. N-acetylglutamate serves as an allosteric activator of carbamylphosphate synthetase 1, which is severely reduced in the absence of N-acetylglutamate (less than 5% of normal). N-acetylglutamate synthase deficiency is inherited as an autosomal recessive trait. For accurate diagnosis, molecular confirmation is recommended (34).

In neonates with congenital urea cycle disorders dying of hyperammonemic coma, neuropathologic changes involve prominent cerebral edema and generalized neuronal cell loss. Survivors of prolonged hyperammonemic coma show neuroimaging abnormalities, such as ventriculomegaly with increased sulcal markings, bilateral symmetrical low-density white matter defects, and diffuse atrophy with sparing of the cerebellum (15). The distribution of age-specific MRI lesions is thought to reflect hypoperfusion secondary to hyperammonemia and hyperglutaminemia, predominantly affecting brain regions with a high metabolic rate (21). Neuropathology in those children who died was consistent with the neuroimaging findings and included ulegyria, cortical atrophy with ventriculomegaly, and prominent cortical neuronal loss.

Liver biopsy shows microvesicular and macrovesicular fat and mitochondria of irregular size and shape with intracristae crystallizations (73). The mechanisms of ammonia-induced brain damage are only partly understood. Ammonia is normally detoxified in astrocytes by mitochondrial glutamate dehydrogenase and cytosolic glutamine synthase. The accumulation of ammonia and subsequently increased astrocytic glutamine production in concert with disturbed autoregulation of cerebral blood perfusion results in a number of deleterious effects on the brain. These include depletion of intermediates of cell energy metabolism and of organic osmolytes, altered amino acid and neurotransmitter concentrations, increased extracellular potassium concentrations (75; 10; 42), potentially altered water transport through aquaporin-4 channels (42), and oxidative and nitrosative stress due to increased free radical production and increased nitric oxide synthesis (48). A zebrafish model was used to analyze the effects of hyperammonemia, demonstrating strongly enhanced transamination-dependent formation of osmolytic glutamine and excitatory glutamate, thereby inducing neurotoxicity and death via synergistically acting overactivation of NMDA receptors and bioenergetic impairment induced by depletion of 2-oxoglutarate. Withdrawal of 2-oxoglutarate from the tricarboxylic acid cycle with consecutive tricarboxylic acid cycle dysfunction ultimately causes impaired oxidative phosphorylation with ATP shortage, decreased ATP/ADP-ratio, and elevated lactate concentrations. Interestingly, inhibition of ornithine aminotransferase is a promising and effective therapeutic approach for preventing neurotoxicity and mortality by hyperammonemia in zebrafish (71; 72).

In vitro experiments demonstrated that hyperammonemia observed in patients receiving valproate may result from a direct inhibition of the N-acetylglutamate synthase activity by valproyl-CoA. Consequently, reduced availability of N-acetylglutamate will impair activation of carbamylphosphate synthetase 1 activity and compromise ammonia detoxification through the urea cycle (02).

Differential diagnosis

Disorders of fatty acid beta-oxidation, organic acid metabolism (including valproate treatment), lactic acidosis, and respiratory chain disorders with increased nicotinamide adenine dinucleotide to nicotinic acid dehydrogenase ratio lead to functional N-acetylglutamate synthase deficiency by depriving the enzyme of its substrate acetyl-CoA, by direct inhibition of the enzyme, or by competing with N-acetylglutamate at the carbamoylphosphate synthetase 1 binding site. Benzoate or phenylbutyrate (phenylacetate) depletes coenzyme A and might also lead to secondary deficiency of N-acetylglutamate synthesis. In acetyl-CoA deficiency, concomitant hypoglycemia occurs because acetyl-CoA stimulates pyruvate carboxylase.

Confusing conditions

A number of inborn errors of metabolism can have a similar clinical presentation to N-acetylglutamate synthase deficiency, especially in the newborn period. These include other urea cycle disorders and amino acidopathies, mitochondriopathies, congenital lactic acidoses, defects in fatty acid beta-oxidation, and organic acidurias. In addition, a number of acquired conditions, including transient hyperammonemia of the newborn, sepsis, intracranial hemorrhage, and cardiorespiratory disorders can present with similar symptoms. Differentiation between these depends first on identifying hyperammonemia associated with specific metabolic patterns of amino acids, acylcarnitines, or organic acid abnormalities. Mitochondrial carbonic anhydrase VA deficiency should also be included in the differential diagnosis (64).

In older children and adults, a number of acquired disorders can also present with hyperammonemia, including liver disease, drug toxicity, and hepatotoxins. Historical information, prothrombin time, a urinary toxic screen, and plasma amino acid pattern should help to differentiate these disorders.

Diagnostic workup

In N-acetylglutamate synthase deficiency, the leading biochemical feature is hyperammonemia. Plasma ammonia levels are elevated from 3- to 20-fold during acute episodes. The workup of a suspected case of N-acetylglutamate synthase deficiency should include measurement of plasma ammonia, lactate, (pyruvate) and amino acids, urinary organic acids, and orotic acid. Defects of the other urea cycle enzymes, related transport proteins, organic acidurias, as well as fatty acid beta-oxidation defects or carnitine deficiency have to be excluded because they lead secondarily to a functional N-acetylglutamate synthase deficiency. The differentiation from carbamoylphosphate synthetase 1 deficiency can be achieved by the difficult enzyme assay in a representative liver biopsy sample (with simultaneous assay of carbamoylphosphate synthetase 1 activity). However, also because insufficient sensitivity of enzyme analysis to discriminate between homo- and heterozygosity of N-acetylglutamate synthase deficiency was reported, molecular diagnostics rather than enzyme analysis should be primarily used in patients suspected of N-acetylglutamate synthase deficiency (25).

A therapeutic trial of N-carbamylglutamate with arginine supplementation has been used as a diagnostic test (23). After an adequate dose of N-carbamylglutamate, a decrease of ammonia can be observed in N-acetylglutamate synthase deficiency, accompanied by an increase of plasma citrulline level, urinary orotic acid excretion, and a marked improvement in protein tolerance (16). N-carbamylglutamate has, therefore, been suggested as an emergency medication in neonatal hyperammonemia of unknown etiology. However, the test is not specific for N-acetylglutamate synthase deficiency (25). It may also be positive in organic acidurias, CPS1D, or other defects, leading to low mitochondrial acetyl-CoA or glutamate (causing a secondary malfunction of the enzyme), and the test may even be negative in N-acetylglutamate synthase deficiency (47). N-carbamylglutamate has been used as symptomatic therapy in organic acidurias (19). It is important to exclude organic acidurias so that appropriate treatment is not delayed when hyperammonemia is corrected by N-carbamylglutamate. Moreover, carbamoylphosphate synthetase 1 deficient patients have been reported to respond to N-carbamylglutamate therapy (34). A positive N-carbamylglutamate test should, therefore, be followed by molecular confirmation of N-acetylglutamate synthase deficiency and exclusion of organic acidurias; otherwise, erroneous treatment might harm the patient. Molecular genetic analysis is nowadays more often used in North America and Europe to confirm diagnosis than measurement of enzymatic activity (52; 34). Because N-acetylglutamate synthase deficiency and carbamoylphosphate synthetase 1 deficiency have identical clinical and laboratory manifestations, Haberle and colleagues have provided an algorithm on how to proceed for differential diagnosis between N-acetylglutamate synthase deficiency and carbamoylphosphate synthetase 1 deficiency (25).

Ammonia is detoxified through its conversion to urea by the enzymes in the small boxes

Very similar is, finally, the mitochondrial carbonic anhydrase VA deficiency, which is also associated with low-normal orotic acid excretion (64).

Management

For a detailed discussion see “Suggested guidelines for the diagnosis and management of urea cycle disorders” (25).

Management of acute hyperammonemia of N-acetylglutamate synthase deficiency.

Table 1. Protein, Liquid, and Glucose Management

Escalation level	NH₃ (µmol/L)	Protein	Liquid IV (ml/kg/d)	Glucose IV (mg/kg/min)	Insulin	Comments*****
1	< 100	Stop*	100 - 150**	10***	i.n.****
2	100 - 250	Stop*	100 - 150**	10***	i.n.****	Inform metabolic clinic
3	250 - 500	Stop*	100 - 150**	10***	i.n.****	Inform dialysis clinic
4	> 500	Stop*	100 - 150**	10***	i.n.****	Hemodialysis
Consensus-based treatment protocol for pediatric (specialized) hospitals treating NAGSD patients with acute hyperammonemia according to “Suggested guidelines for the diagnosis and management of urea cycle disorders” (25). Stop protein intake for 24 hours (maximum 48 hours) Liquid management might be adapted to hospital- and age-specific requirements Glucose management might be adapted to age-specific requirements If necessary (i.n.) give 0.05 units/kg/h ***Hyperglycemia can be dangerous, monitor every 0.5 - 1 hour; monitor blood ammonia levels every 3 hours; monitor electrolytes, blood gases and lactate regularly, eg, every 3 hours

Table 2. First-Line Medication for NAGSD****

Esca-lation level	NH₃ (µmol/L)	Sodium benzoate IV***		Sodium benzoate or phenylacetate (Ammonul ®) IV		L-Arginine hydro-chloride 21% IV***		Carbamyl-glutamate by mouth
Esca-lation level	NH₃ (µmol/L)	Bolus (mg/kg) in 90 – 120 min	Mainten-ance (mg/kg/d)**	Bolus (mg/kg) in 90 – 120 min	Maintenance (mg/kg/d)	Bolus (mg/kg) in 90 – 120 min	Mainten-ance (mg/kg/d)	Carbamyl-glutamate by mouth
1	< 100	/	/	/	/	/	/	Bolus:100 mg/kg Maintenance: 25 – 62.5 mg/kg every 6 hours
2	100 - 250	250	250 – 500 5.5 g/m2/d *	/	/	250	250
3	250 - 500	250	250 – 500 5.5 g/m2/d *	/	/	250	250
4	> 500	250	250 – 500 5.5 g/m2/d *	/	/	250	250
Consensus-based treatment protocol for pediatric (specialized) hospitals treating NAGSD patients with acute hyperammonemia according to “Suggested guidelines for the diagnosis and management of urea cycle disorders” (25). If patient weighs more than 20 kg If on dialysis maintenance doses should increase to 350 mg/kg/d First-line medications must be diluted in 10% glucose prior to IV application. (Caution: L-arginine-HCl may cause metabolic acidosis and extravasation may lead to tissue necrosis) **Control electrolytes due to possible danger of hypernatremia and hypokalemia

In the newborn period, management of acute hyperammonemia may be anticipatory or reactive. In families who have had an index patient, the birth of an at-risk or prenatally diagnosed infant provides the opportunity for prospective management. When N-acetylglutamate synthase deficiency is known, suspected, or even before a definite diagnosis has been made, in cases of acute hyperammonemia, N-carbamylglutamate should be administered (25). N-carbamylglutamate (Carbaglu ®) should be applied initially as bolus at a dose of 100 mg/kg and subsequently every 6 hours at a dose of 25 mg/kg to 62.5 mg/kg. Unfortunately, there is no parenteral application available thus far, so N-carbamylglutamate has to be administered orally or via nasogastric tube if oral intake is not possible.

For newborns or infants who have been diagnosed with hyperammonemic coma, therapy must not be delayed because coma duration of fewer than 1.5 days (51), and timely start of treatment are very important determinants of outcome. An analysis showed that noninterventional variables (eg, disease onset and initial peak-ammonium concentrations) are of utmost importance for neurologic outcomes in individuals with urea cycle disorders (53). Large ongoing studies from the E-IMD and UCDC consortia aim to investigate the effect of (early) diagnosis and treatment principles on the neurologic and cognitive outcomes of affected individuals (54). Specialized pediatric hospitals should have first-line medications, consensus-based treatment protocols, and must act according to the following principles:

• (1) Stop protein intake (see Table 1)
• (2) Start intravenous fluid and glucose substitution (see Table 1)
• (3) Start first-line medication (see Table 2)

Suggestions for a consensus-based treatment protocol, following the above-outlined principles, are depicted in Tables 1 and 2. Each (specialized) pediatric hospital should be able to adapt these recommendations to facility-specific conditions to provide best-care medicine for their patients and prevent delay of treatment.

Ammonia scavengers, (sodium benzoate and sodium phenylacetate/-butyrate) provide alternate pathways to eliminate waste nitrogen (08). A few studies demonstrate that treatment with sodium benzoate and sodium phenylbutyrate is safe and effective for the treatment or prevention of hyperammonemia in urea cycle disorders (32; 07). Sodium benzoate is conjugated with glycine to form hippurate and sodium phenylbutyrate is conjugated with glutamine to form phenylacetylglutamine, both of which are cleared by the kidneys. Glutamine contains two nitrogen atoms. Thus, two moles of waste nitrogen are removed for each mole of phenylacetate/-butyrate administered.

Theoretically, on a mole-per-mole basis, nitrogen-disposing efficacy of sodium phenylbutyrate should be twice that of sodium benzoate and although biochemical superiority of sodium phenylbutyrate has been demonstrated (45), no systematic studies regarding the effects of long-term pharmacotherapy on neurologic or cognitive outcome, as defined by clinical endpoints, exist thus far for NAGS-deficiency (45). Energy is supplemented via oral, nasogastric, or intravenous routes by 20% to 100% above the recommended daily requirements using carbohydrates (such as glucose orally or dextrose 20% orally or glucose intravenously), and fat (intralipid 20%), starting at 1 g/kg and increased up to 3 g/kg per day. However, a multicenter study showed that during the first 24 hours of emergency treatment, caloric intake was lower than during maintenance treatment. Carbohydrates were the primary, if not sole, energy source, but were below age-adapted recommendations, and fat was often omitted from initial emergency treatment (53). It may become necessary to provide soluble insulin to support intracellular glucose uptake and to avoid hyperglycemia. The intake of natural protein is stopped for 24 to maximally 48 hours and is then reintroduced gradually as tolerated (31). In the event that ammonium concentrations do not respond to this management and biochemical or clinical symptoms worsen, continuous venovenous hemodiafiltration (CVVHDF) should be started immediately (planned and organized earlier, ie, at levels > 400 µmol/L) in neonates or children with ammonia levels of more than 500 µmol/L or at lower levels if response to medical treatment is inadequate. Note, even though CVVHDF is by far the most efficient method for extracorporal ammonia elimination (51), prognosis is not related to dialysis modality, but primarily to the duration of coma before the start of treatment, confirming the necessity for rapid and aggressive management. In fact, a retrospective data analysis of 202 published cases revealed that dialysis does not impact outcome, and only 20% of all investigated individuals had a normal clinical outcome. In conclusion, dialysis along with conservative pharmacotherapeutic treatment is recommended to be initiated as early as possible and at lower ammonium concentrations (30); however, long-term data analyzing these recommendations is not available.

The dietary aim is to minimize external protein and, thus, nitrogen intake and at the same time to prevent endogenous protein catabolism by meeting the high-energy demands of the patient. The initial dietary emergency regimen should be protein-free, but protein or essential amino acids must be reintroduced after 24 to 48 hours or once blood ammonia level has fallen below 100 µmol/L (25). In addition to close-meshed control of laboratory parameters like ammonia, electrolytes, glucose, etc., plasma amino acids must be determined and the results available daily to safely stir such management. The reduction of protein intake must be carefully monitored to prevent overrestriction. A diet with inadequate intake can impair protein synthesis and lead to catabolic metabolic decompensation or failure to thrive (31).

After diagnosis of N-acetylglutamate synthase deficiency, no special emergency treatment may be necessary during intercurrent illnesses except continuing the regular administration of N-carbamylglutamate. If necessary, protein, liquid, and glucose management to treat intercurrent hyperammonemic episodes is identical to the protocol in Table 1. Patients and families might start with an oral emergency dietary regimen at home. Antipyretic measurements must be consequently carried out if temperature exceeds 38°C; patients and parents must be aware that these measures must not postpone or replace adequate emergency treatment in the hospital (31; 74).

Patients should be supplied with an emergency card, letter, or bracelet containing instructions for emergency measures and phone numbers. The logistics of rational therapeutic measures should be repeatedly evaluated by the specialist team with the family and the primary care physicians.

Long-term management of NAGSD.

Table 3. Long-Term Medication for NAGSD

	Sodium benzoate by mouth	Sodium phenylbutyrate by mouth		L-Arginine by mouth		L-Citrulline by mouth	Carbamyl-glutamate by mouth
	(in mg/kg/d)	< 20 kg (in mg/kg/d)	> 20 kg (in g/m²/d)	< 20 kg (in mg/kg/d)	> 20 kg (in g/m²/d)		(in mg/kg/d)
Dose	/	/	/	(100 – 200)	(2.5 – 6)	/	10 – 100
Maximum	/	/		(6 g/d)		/	/

Consensus-based long-term treatment protocol for pediatric (specialized) hospitals treating patients with NAGSD according to suggested guidelines for the diagnosis and management of urea cycle disorders (25).

Long-term management of N-acetylglutamate synthase deficiency relies on the goals of preventing recurrent hyperammonemia and neurologic sequelae and improving quality of life by the following principles (31; 25):

• (1) Long-term medication (see Table 3)
• (2) If individually necessary, avoidance of catabolism
• (3) Suitable emergency regimens in intercurrent illness (see Tables 1 and 2)

Early identification and treatment of intercurrent hyperammonemic episodes is essential both because treatment is more effective at lower ammonium concentrations and because neurologic outcome appears to be a function of duration of severe hyperammonemia (50). Obviously, the subtle regulation of the urea cycle is not fully restored by treatment with carbamylglutamate.

Catabolism must be avoided to trigger metabolic decompensation. In addition to intercurrent illnesses, especially if associated with high fever and decreased intake of food and fluids, dangerous triggers are severe exercise, seizures, trauma or burns, steroid administration, chemotherapy, and gastrointestinal hemorrhage.

Unlike other urea cycle disorders, long-term treatment of N-acetylglutamate synthase deficiency does usually not require dietary management except during metabolic crises (see above). The standard N-carbamylglutamate maintenance dosage of approximately 100 mg/kg/d (given in 3-4 doses) should be adjusted individually by down-titration to the minimum dose required (usually 10-15 mg/kg/d (Table 3)) (25). N-carbamylglutamate is an analogue of N-acetylglutamate but unlike N-acetylglutamate, can readily cross the mitochondrial membrane and activate carbamoylphosphate synthase 1. The in vivo effect on ureagenesis in patients with N-acetylglutamate synthase deficiency and propionic acidemia has been confirmed in tracer studies (12; 63; 70). Doses greater than 650 mg/kg can lead to the clinical picture of glutamate intoxication, causing tachycardia, sweating, bronchial hypersecretion, elevated body temperature, and restlessness (57). N-carbamylglutamate treatment leads to a moderate increase of glutamine concentration in plasma. In cases of low plasma L-arginine (or L-citrulline) levels, the essential amino acid L-arginine (or L-citrulline, which is converted to L-arginine) should be provided at a dose of 100 to 200 mg/kg/d both as an essential missing product and to activate or stabilize residual N-acetylglutamate synthase activity to produce N-acetylglutamate.

However, a study demonstrated that all individuals with N-acetylglutamate synthase receiving long-term medication were treated solely with N-carbamylglutamate, unlike L-arginine or L-citrulline, which were only sporadically administered (53). This observation was confirmed by a published review, demonstrating that L-arginine, L-citrulline, or nitrogen scavengers were only rarely used in addition to L-carbamylglutamate with or without a protein-restricted diet (34).

Occasionally, protein intake restriction may be necessary, depending on the response to N-carbamylglutamate. However, the stimulation of alternate pathways of waste nitrogen excretion (sodium benzoate, sodium/glycerol phenylbutyrate) is usually unnecessary and would consume coenzyme A, one of the substrates of N-acetylglutamate synthase and ATP, which is needed for CPS1 activation (55). Transporters involved in renal excretion of N-carbamylglutamate have been identified. Schwob and colleagues proposed that N-carbamylglutamate is taken up at the basolateral membrane of kidney proximal tubule renal cells by the organic anion transporter 1 (OAT1) in cooperation with the sodium dicarboxylate cotransporter 3 (NaDC3). Efflux across the luminal membrane into the tubular lumen probably occurs by OAT4, completing renal secretion of N-carbamylglutamate (58). Periodic measurements of plasma amino acids (which include glutamine) and blood ammonia may permit adjustment of therapy before clinical symptoms appear. The benefit of vaccinations outweighs the risk of decompensations. They are recommended at the same schedule as for healthy children (44; 25).

Some medications are contraindicated in urea cycle disorders because of secondary inhibition of the urea cycle or inducing catabolism, most importantly valproic acid and systemic steroids. Even in well-controlled and managed patients, peracute deadly coma can occur. Less often but also to be considered is the potential development of hyperammonemic crises by the treatment with carbamazepine, the use of asparaginase or 5-fluorouracil in cancer therapy or bladder, uterine, or joint irrigation with glycine solution during surgery.

Liver transplantation might also be a suitable treatment for individuals with N-acetylglutamate synthase deficiency that do not reach a stable metabolic condition despite intensive conservative treatment. A study suggested that individuals with urea cycle disorders had an improved neurocognitive outcome if they received a liver graft, suggesting that they should undergo liver transplantation already after comparatively low maximum ammonium concentrations to protect the patient’s neurocognitive abilities (37; 36). However, further data suggest a rather limited impact of liver transplantation on the neurodevelopmental outcomes of individuals with a severe disease burden (35). Hepatocyte transplantation is an interesting therapeutic bridging option in patients with urea cycle disorder awaiting liver transplantation (43) and is investigated in studies.

An interesting approach for treatment of acute hyperammonemia is the inhibition of ornithine aminotransferase, leading to a transamination-dependent decrease of glutamate and glutamine. Mammalian transfer will provide more insight if this approach is indeed a potential therapeutic principle for individuals with urea cycle disorders (71). Lately, it was suggested that autophagy cooperates with the urea cycle in ammonia homeostasis. Selective activation of hepatic autophagy might, therefore, be used to treat hyperammonemia due to acquired or inherited diseases. However, it remains to be elucidated if autophagy might also play an important role during hyperammonemic conditions in the brain in order to determine if autophagy might be a suitable target for treatment of hyperammonemic conditions (60).

Outcomes

Although some publications suggest an improved outcome (eg, neurologic manifestation, mortality) of individuals with urea cycle disorders, a review and metaanalysis showed less convincing results, suggesting that no substantial improvement of survival for urea cycle disorders was observed over more than 3 decades between 1978 and 2014 (09). Some studies showed that noninterventional variables reflecting disease severity are associated with the highest risk of mortality and poor neurologic outcome (17; 53). Long-term morbidity is still substantial in individuals with urea cycle disorders. A transatlantic study with more than 500 individuals evaluated the impact of the initial peak blood ammonium concentration on their cognitive outcome, revealing that high initial peak blood ammonium concentrations adversely affect cognition in proximal (including NAGS-deficiency) rather than distal urea cycle disorders (54). More research is needed in order to evaluate the pathomechanistic basis for this finding and to study further predictors of good and poor neurocognitive outcomes in individuals with urea cycle disorders.

Special considerations

Pregnancy

It is unclear how pregnancies would affect women with N-acetylglutamate synthase deficiencies. There have been no published reports of pregnancies in affected females.

Langendonk and colleagues studied a series of pregnancies in women with inherited metabolic disease and suggested that special care must be taken not to confuse behavioral changes of hyperammonemia for symptoms of postpartum psychosis or depression (41). Routine monitoring of plasma ammonia levels in those women was suggested (18). Therefore, pregnancies in women with inherited metabolic disease should be monitored and escorted in close contact with or better in a medical center that includes a metabolic center (41).

Anesthesia

There has been one report of hyperammonemia induced by enflurane in argininosuccinic aciduria (04). It is prudent to use anesthetics with low toxicity to the liver. However, surgery requires stopping of oral medication and may be associated with a catabolic condition, both of which may induce hyperammonemia. It is important to resume oral medication of N-carbamylglutamate as soon as possible and, if necessary, start alternate pathway therapy intravenously until the patient is able to tolerate his oral medication. The patient should also receive adequate glucose infusion to prevent catabolism. Surgery should only be carried out in centers prepared for dealing with acute hyperammonemic episodes. After surgery, close monitoring of the clinical status and ammonia and glutamine levels as well as shifting to oral medications are required (25).

A case was reported emphasizing that appropriate guidelines for the pre- and postoperative care of patients with inherited metabolic diseases of the urea cycle are indispensable (20).

References

01: Ah Mew N, Caldovic L. N-acetylglutamate synthase deficiency: an insight into the genetics, epidemiology, pathophysiology, and treatment. Appl Clin Genet 2011;4:127-35. PMID 23776373
02: Aires CC, van Cruchten A, Ijlst L, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 2011;55(2):426-34. PMID 21147182
03: Al Kaabi EH, El-Hattab AW. N-acetylglutamate synthase deficiency: novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra. Mol Genet Metab Rep 2016;8:94-8. PMID 27570737
04: Asai K, Ishii S, Ohta S, Furusho K. Fatal hyperammonemia in argininosuccinic aciduria following enflurane anesthesia. Eur J Pediatr 1998;157(2):169-70. PMID 9504797
05: Bachmann C. Outcome and survival of 88 patients with urea cycle disorders: a retrospective evaluation. Eur J Pediatr 2003;162(6):410-6. PMID 12684900
06: Bachmann C, Krahenbuhl S, Colombo JP, et al. N-acetylglutamate synthetase deficiency: a disorder of ammonia detoxication. N Engl J Med 1981;304:543. PMID 7453791
07: Berry SA, Longo N, Diaz GA, et al. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. Mol Genet Metab 2017;122(3):46-53. PMID 28916119
08: Brusilow S, Tinker J, Batshaw ML. Amino acid acylation: a mechanism of nitrogen excretion in inborn errors of urea synthesis. Science 1980;207(4431):659-61. PMID 6243418
09: Burgard P, Kölker S, Haege G, Lindner M, Hoffmann GF. Neonatal mortality and outcome at the end of the first year of life in early onset urea cycle disorders-review and meta-analysis of observational studies published over more than 35 years. J Inherit Metab Dis 2016;39(2):219-29. PMID 26634836
10: Butterworth R. Neuronal cell death in hepatic encephalopathy. Metab Brain Dis 2007;22(3-4):309-20. PMID 17851742
11: Caldovic L, Ah Mew N, Shi D, Morizono H, Yudkoff M, Tuchman M. N-acetylglutamate synthase: structure, function and defects. Mol Genet Metab 2010;100(Suppl 1):S13-9. PMID 20303810
12: Caldovic L, Morizono H, Panglao MG, Cheng SF, Packman S, Tuchman M. Null mutations in the N-acetylglutamate synthase gene associated with acute neonatal disease and hyperammonemia. Hum Genet 2003;112(4):364-8. PMID 12594532
13: Cartagena A, Prasad AN, Rupar CA, et al. Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults. Can J Neurol Sci 2013;40(1):3-9. PMID 23250120
14: Cavicchi C, Chilleri C, Fioravanti A, et al. Late-onset N-acetylglutamate synthase deficiency: report of a paradigmatic adult case presenting with headaches and review of the literature. Int J Mol Sci 2018;19(2). PMID 29364180
15: Choi CG, Yoo HW. Localized proton MR spectroscopy in infants with urea cycle defect. AJNR Am J Neuroradiol 2001;22(5):834-7. PMID 11337324
16: Elpeleg O, Shaag A, Ben-Shalom E, Schmid T, Bachmann C. N-acetylglutamate synthase deficiency and the treatment of hyperammonemic encephalopathy. Ann Neurol 2002;52(6):845-9. PMID 12447942
17: Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007;356(22):2282-92. PMID 17538087
18: Fassier T, Guffon N, Acquaviva C, D'Amato T, Durand DV, Domenech P. Misdiagnosed postpartum psychosis revealing a late-onset urea cycle disorder. Am J Psychiatry 2011;168(6):576-80. PMID 21642480
19: Filippi L, Gozzini E, Fiorini P, Malvagia S, la Marca G, Donati MA. N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. Neonatology 2010;97(3):286-90. PMID 19887858
20: Gharavifard M, Sabzevari A, Eslami R. Anesthetic management in a child with citrullinemia: a case report. Anesth Pain Med 2014;4(3):e21791. PMID 25289380
21: Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab 2010;100 Suppl 1:S20-30. PMID 20207564
22: Gropman AL, Prust M, Breeden A, Fricke S, VanMeter J. Urea cycle defects and hyperammonemia: effects on functional imaging. Metab Brain Dis 2013;28(2):269-75. PMID 23149878
23: Guffon N, Schiff M, Cheillan D, Wermuth B, Haberle J, Vianey-Saban C. Neonatal hyperammonemia: the N-carbamoylglutamic acid test. J Pediatr 2005;147(2):260-2 PMID 16126063
24: Gunz AC, Choong K, Potter M, Miller E. Magnetic resonance imaging findings and neurodevelopmental outcomes in neonates with urea-cycle defects. Int Med Case Rep J 2013;6:41-8. PMID 23983495
25: Haberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. J Inherit Metab Dis 2019;42(6):1192-230. PMID 30982989
26: Haberle J, Koch HG. Genetic approach to prenatal diagnosis in urea cycle defects. Prenat Diagn 2004;24:378-83. PMID 15164414
27: Haberle J, Moore MB, Haskins N, et al. Noncoding sequence variants define a novel regulatory element in the first intron of the N-acetylglutamate synthase gene. Hum Mutat 2021;42(12):1624-36. PMID 34510628
28: Haberle J, Schmidt E, Pauli S, et al. Mutation analysis in patients with N-acetylglutamate synthase deficiency. Hum Mutat 2003;21(6):593-7. PMID 12754705
29: Heckmann M, Wermuth B, Haberle J, Koch HG, Gortner L, Kreuder JG. Misleading diagnosis of partial N-acetylglutamate synthase deficiency based on enzyme measurement corrected by mutation analysis. Acta Pædiatrica 2005;94(1):121-4 PMID 15858972
30: Hediger N, Landolt MA, Diez-Fernandez C, Huemer M, Haberle J. The impact of ammonia levels and dialysis on outcome in 202 patients with neonatal onset urea cycle disorders. J Inherit Metab Dis 2018;41(4):689-98. PMID 29520739
31: Hoffmann GF, Zschocke J, Nyhan WL. Inherited metabolic diseases - a practical approach. Heidelberg: Springer, 2017.
32: Husson MC, Schiff M, Fouilhoux A, et al. Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study. Orphanet J Rare Dis 2016;11(1):127. PMID 27663197
33: Jamiolkowski D, Kölker S, Glahn EM, et al. Behavioural and emotional problems, intellectual impairment and health-related quality of life in patients with organic acidurias and urea cycle disorders. J Inherit Metab Dis 2016;39(2):231-41. PMID 26310964
34: Kenneson A, Singh RH. Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature. Orphanet J Rare Dis 2020;15(1):279.** PMID 33036647
35: Kido J, Matsumoto S, Häberle J, et al. Role of liver transplantation in urea cycle disorders: report from a nationwide study in Japan. J Inherit Metab Dis 2021;44(6):1311-22. PMID 34232532
36: Kido J, Matsumoto S, Mitsubuchi H, Endo F, Nakamura K. Early liver transplantation in neonatal-onset and moderate urea cycle disorders may lead to normal neurodevelopment. Metab Brain Dis 2018;33(5):1517-23. PMID 29948653
37: Kido J, Matsumoto S, Momosaki K, et al. Liver transplantation may prevent neurodevelopmental deterioration in high-risk patients with urea cycle disorders. Pediatr Transplant 2017;21(6). PMID 28608518
38: Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis 2012;35(5):777-85.** PMID 22167275
39: Kolker S, Cazorla AG, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. J Inherit Metab Dis 2015a;38(6):1155-6.** PMID 26077420
40: Kolker S, Valayannopoulos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis 2015b;38(6):1157-8.** PMID 26077421
41: Langendonk JG, Roos JC, Angus L, et al. A series of pregnancies in women with inherited metabolic disease. J Inerhit Metab Dis 2012;35(3):419-24. PMID 21918856
42: Lichter-Konecki U, Mangin JM, Gordish-Dressman H, Hoffman EP, Gallo V. Gene expression profiling of astrocytes from hyperammonemic mice reveals altered pathways for water and potassium homeostasis in vivo. Glia 2008a;56:365-77. PMID 18186079
43: Meyburg J, Opladen T, Spiekerkötter U, et al. Human heterologous liver cells transiently improve hyperammonemia and ureagenesis in individuals with severe urea cycle disorders. J Inherit Metab Dis 2018;41(1):81-90. PMID 29027067
44: Morgan TM, Schlegel C, Edwards KM, et al. Vaccines are not associated with metabolic events in children with urea cycle disorders. Pediatrics 2011;127(5):e1147-53. PMID 21482610
45: Nagamani SCS, Agarwal U, Tam A, et al. A randomized trial to study the comparative efficacy of phenylbutyrate and benzoate on nitrogen excretion and ureagenesis in healthy volunteers. Genet Med 2018;20(7):708-16. PMID 29693650
46: Nettesheim S, Kölker S, Karall D, et al. Incidence, disease onset and short-term outcome in urea cycle disorders -cross-border surveillance in Germany, Austria and Switzerland. Orphanet J Rare Dis 2017;12(1):111. PMID 28619060
47: Nordenström A, Halldin M, Hallberg B, Alm J. A trial with N-carbamylglutamate may not detect all patients with NAGS deficiency and neonatal onset. J Inherit Metab Dis 2007;30(3):400. PMID 17510757
48: Norenberg MD, Jayakumar AR, Rama Rao KV, Panickar KS. New concepts in the mechanism of ammonia-induced astrocyte swelling. Metab Brain Dis 2007;22(3-4):219-34. PMID 17823859
49: Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A. Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognized ornithine transcarbamylase deficiency. J Neurol Neurosurg Psychiatry 1998;64(5):680-2. PMID 9598692
50: Peoc’h K, Damaj L, Pelletier R, et al. Early care of N-acetyl glutamate synthase (NAGS) deficiency in three infants from an inbred family. Mol Genet Metab Rep 2020;22:100558. PMID 32021803
51: Picca S, Dionisi-Vici C, Abeni D, et al. Extracorporal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. Pediatr Nephrol 2001;16(11):862-7. PMID 11685590
52: Posset R, Garbade SF, Boy N, et al. Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders-a successful strategy for clinical research of rare diseases. J Inherit Metab Dis 2019b;42(1):93-106. PMID 30740724
53: Posset R, Garcia-Cazorla A, Valayannopoulos V, et al. Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders. J Inherit Metab Dis 2016;39(5):661-72. PMID 27106216
54: Posset R, Gropman AL, Nagamani SCS, et al. Impact of diagnosis and therapy on cognitive function in urea cycle disorders. Ann Neurol 2019a;86(1):116-28. PMID 31018246
55: Rubio V, Britton HG, Grisolia S. Mitochondrial carbamoyl phosphate synthetase activity in the absence of N-acetyl-L-glutamate. Mechanism of activation by this cofactor. Eur J Biochem 1983;134:337-43. PMID 6223815
56: Sancho-Vaello E, Marco-Marin C, Gougeard N, et al. Understanding N-acetyl-L-glutamate synthase deficiency: mutational spectrum, impact of clinical mutations on enzyme functionality, and structural considerations. Hum Mutat 2016;37(7):679-94. PMID 27037498
57: Schubiger G, Bachmann C, Barben P, et al. N-acetylglutamate synthetase deficiency, diagnosis, management and follow-up of a rare disorder of ammonia detoxication. Eur J Pediatr 1991;150:353-6. PMID 2044610
58: Schwob E, Hagos Y, Burckhardt G, Burckhardt BC. Transporters involved in renal excretion of N-carbamoylglutamate, an orphan drug to treat inborn n-acetylglutamate synthase deficiency. Am J Physiol Renal Physiol 2014;307(12):F1373-9. PMID 25354943
59: Sonaimuthu P, Senkevitch E, Haskins N, et al. Gene delivery corrects N-acetylglutamate synthase deficiency and enables insights in the physiological impact of L-arginine activation of N-acetylglutamate synthase. Sci Rep 2021;11(1):3580. PMID 33574402
60: Soria LR, Brunetti-Pierri N. Ammonia and autophagy: an emerging relationship with implications for disorders with hyperammonemia. J Inherit Metab Dis 2019;42(6):1097-104. PMID 30671986
61: Summar ML, Endo F, Kölker S. On the creation, utility and sustaining of rare diseases research networks: lessons learned from the Urea Cycle Disorders Consortium, the Japanese Urea Cycle Disorders Consortium and the European Registry and Network for Intoxication Type Metabolic Diseases. Mol Genet Metab 2014;113(1-2):105-8.** PMID 25261246
62: Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. Mol Genet Metab 2013;110(1-2):179-80. PMID 23972786
63: Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res 2008;64(2):213-7. PMID 18414145
64: van Karnebeek CD, Sly WS, Ross CJ, et al. Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A alterations presents with hyperammonemia in early childhood. Am J Hum Gen 2014;94(3):453-61. PMID 24530203
65: Van Leynseele A, Jansen A, Goyens P, et al. Early treatment of a child with NAGS deficiency using N-carbamyl glutamate results in a normal neurological outcome. Eur J Pediatr 2014;173(12):1635-8. PMID 24233332
66: Vasquez-Loarte T, Thompson JD, Merritt JL 2nd. Considering proximal urea cycle disorders in expanded newborn screening. Int J Neonatal Screen 2020;6(4):77. PMID 33124615
67: Vockley J, Walsh-Vockley CM, Lin SP, et al. Normal N-acetylglutamate concentration measured in liver from a new patient with N-acetylglutamate synthetase deficiency: physiologic and biochemical implications. Biochem Med Metab Biol 1992;47:38-46. PMID 1562355
68: Waisbren SE, Gropman AL, Members of the Urea Cycle Disorders Consortium (UCDC), Batshaw ML. Improving long term outcomes in urea cycle disorders-report from the Urea Cycle Disorders Consortium. J Inherit Metab Dis 2016;39(4):573-84. PMID 27215558
69: Williams M, Burina A, Rubert L, et al. N-acetylglutamate synthase deficiency due to a recurrent sequence variant in the N-acetylglutamate synthase enhancer region. Sci Rep 2018;8(1):15436. PMID 30337552
70: Yudkoff M, Ah Mew N, Daikhin Y, et al. Measuring in vivo ureagenesis with stable isotopes. Mol Genet Metab 2010;100(Suppl 1):S37-41. PMID 20338795
71: Zielonka M, Breuer M, Okun JG, et al. Pharmacologic rescue of hyperammonemia-induced toxicity in zebrafish by inhibition of ornithine aminotransferase. PLoS One 2018;13(9):e0203707.** PMID 30199544
72: Zielonka M, Probst J, Carl M, Hoffmann GF, Kolker S, Okun JG. Bioenergetic dysfunction in a zebrafish model of acute hyperammonemic decompensation. Exp Neurol 2019;314:91-9. PMID 30653968
73: Zimmermann A, Bachmann C, Schubiger G. Liver pathology in a new congenital disorder of urea synthesis: N-acetylglutamate synthetase deficiency. Virchows Arch (Pathol Anat) 1985;408:259-68. PMID 3936265
74: Zschocke J, Hoffmann GF. Vademecum metabolicum: manual of metabolic paediatrics. 5th edition. Stuttgart: Schattauer Verlag, 2020.
75: Zwingmann C, Chatauret N, Rose C, Leibfritz D, Butterworth RF. Selective alterations of brain osmolytes in acute liver failure: protective effect of mild hypothermia. Brain Res 2004;999(1):118-23. PMID 14746928

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Roland Posset MD

Dr. Posset of the University Center for Child and Adolescent Medicine in Heidelberg received consultancy fees from Immedica Pharma AB.
See Profile
Matthias Zielonka MD

Dr. Zielonka of University Children’s Hospital Heidelberg has no relevant financial relationships to disclose.
See Profile
Georg F Hoffmann MD

Dr. Hoffmann of the University Center for Child and Adolescent Medicine in Heidelberg has no relevant financial relationships to disclose.
See Profile

Editor

Barry Wolf MD PhD

Dr. Wolf of Lurie Children's Hospital of Chicago has no relevant financial relationships to disclose.
See Profile

Former Authors

Claude Bachmann MD, Uta Lichter-Konecki MD PhD, and Mark L Batshaw MD

Patient Profile

Age range of presentation: 0 month to 12 years
Sex preponderance: male=female
Heredity: autosomal recessive
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Disorders of urea cycle metabolism: 270.6
ICD-10: Disorders of urea cycle metabolism: E72.2
OMIM: N-acetylglutamate synthase deficiency: #237310

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

N-acetylglutamate synthase deficiency

Associated Disorders

Ataxia
Cerebral palsy
Congenital hyperammonemia
Intellectual disability
Valproate sensitivity
- Urea cycle disorders (others)
- Hyperinsulinism-hyperammonemia syndrome
- Lysinuric protein intolerance
- Hyperornithinemia - hyperammonemia - homocitrullinuria syndrome
- Carbonic anhydrase VA deficiency
- Maple syrup urine disease
- Ornithine transcarbamylase deficiency
- Reye syndrome

Differential Diagnosis

urea cycle disorders (others)
amino acidopathies
congenital lactic acidoses
defects in fatty acide beta-oxidation
organic acidurias
- transient hyperammonemia of the newborn
- sepsis
- intracranial hemorrhage
- cardiorespiratory disorders
- valproate treatment
- hypoglycemia
- Reye syndrome
- hyperinsulinism-hyperammonemia syndrome
- liver disease
- drug toxicity
- hepatotoxins
- Mitochondrial carbonic anhydrase VA deficiency

Also Relevant

Ataxia
Carbamoyl phosphate synthetase 1 deficiency
Cerebral palsy
Hyperammonemia not caused by liver failure
Intellectual disability
- Ornithine transcarbamylase deficiency
- Valproic acid

Clinical Categories

Neurogenetic Disorders

Web References

Guidelines

NORD: Urea cycle disorders

N-acetylglutamate synthase deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Management of acute hyperammonemia of N-acetylglutamate synthase deficiency.

Table 1. Protein, Liquid, and Glucose Management

Table 2. First-Line Medication for NAGSD****

Long-term management of NAGSD.

Table 3. Long-Term Medication for NAGSD

Outcomes

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Vanishing white matter disease

Wilson disease

White matter abnormalities in the brain

Hypermethioninemia

POLG-related mitochondrial disorders

Multiple acyl-CoA dehydrogenase deficiency

Medium-chain acyl-CoA dehydrogenase deficiency

Long-chain fatty acid oxidation defects

This is an article preview.
Start a Free Account
to access the full version.